Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 16/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549730 | 0.78 | PARP1 (0.76) | USP2PARP1PARP2MEN1KMT2A | |
| SCHEMBL11943395 | 0.76 | MAPT (0.42) | KMT2AALDH1A1MAPT | |
| SCHEMBL11943391 | 0.76 | SMN1; SMN2 (0.47) | ALDH1A1MAPT | |
| SCHEMBL11943474 | 0.75 | FAAH (0.49) | USP2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL11943482 | 0.74 | GFER (0.58) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL14082616 | 0.74 | HTR1A (0.52) | USP2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL17058594 | 0.74 | GRM5 (0.43) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11943384 | 0.74 | DCTPP1 (0.55) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11943479 | 0.73 | KMT2A (0.49) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11943477 | 0.73 | ALDH1A1 (0.50) | KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | USP2 3913/4885PARP1 380/4885PARP2 647/4885 |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | USP2 3472/4885PARP1 2206/4885PARP2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.